glp 1 oral novo nordisk GLP-1 Wegovy chases approval in obesity Novo Nordisk to launch Ozempic

Bimagrumab has the potential of improving the WL quality by preserving lean mass and could become an attractive treatment option for sarcopenic obesity

In 2023, the average representation of GLP-1 drugs used for weight loss in employers total annual claims was 6.9%, according to survey respondents

Newsome can help you achieve success in a safe, proven way, making sure you have all the support you need

The growing demand for GLP-1s in the workplace As medications like Ozempic, Wegovy, and Zepbound continue to rise in popularity, more employees see GLP-1 access as a must-have job benefit

Not for human consumption, veterinary use, or diagnostic purposes.

Its for anyone who has started to notice that their body doesnt quite respond the way it used to